Melanomas with activating RAF1 fusions: clinical, histopathologic, and molecular profiles

[1]  M. Donati,et al.  Spitz Tumors With ROS1 Fusions: A Clinicopathological Study of 6 Cases, Including FISH for Chromosomal Copy Number Alterations and Mutation Analysis Using Next-Generation Sequencing. , 2020, The American Journal of dermatopathology.

[2]  James X. Sun,et al.  A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability–High Cases in 67,000 Patient Samples , 2019, The Journal of molecular diagnostics : JMD.

[3]  S. Raimondi,et al.  Pathologic Characteristics of Spitz Melanoma With MAP3K8 Fusion or Truncation in a Pediatric Cohort , 2019, The American journal of surgical pathology.

[4]  I. Yeh,et al.  Filigree-like Rete Ridges, Lobulated Nests, Rosette-like Structures, and Exaggerated Maturation Characterize Spitz Tumors With NTRK1 Fusion , 2019, The American journal of surgical pathology.

[5]  R. Tothill,et al.  Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion. , 2019, The Journal of clinical investigation.

[6]  F. Tirode,et al.  Malignant melanoma with areas of rhabdomyosarcomatous differentiation arising in a giant congenital nevus with RAF1 gene fusion , 2019, Pigment cell & melanoma research.

[7]  J. Malvehy,et al.  Genetic Abnormalities in Large to Giant Congenital Nevi: Beyond NRAS Mutations. , 2019, The Journal of investigative dermatology.

[8]  K. White,et al.  Genomic Fusions in Pigmented Spindle Cell Nevus of Reed , 2018, The American journal of surgical pathology.

[9]  A. Shoushtari,et al.  Primary and Metastatic Melanoma With NTRK Fusions , 2018, The American journal of surgical pathology.

[10]  Philip J. Stephens,et al.  A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal , 2018, PLoS Comput. Biol..

[11]  M. Singer,et al.  Significant Clinical Response to a MEK Inhibitor Therapy in a Patient With Metastatic Melanoma Harboring an RAF1 Fusion. , 2018, JCO precision oncology.

[12]  A. Resnick,et al.  CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles , 2017, Oncogene.

[13]  Catherine A. Shang,et al.  Whole-genome landscapes of major melanoma subtypes , 2017, Nature.

[14]  Levi Garraway,et al.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.

[15]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[16]  Pedram Gerami,et al.  A Comparison of Morphologic and Molecular Features of BRAF, ALK, and NTRK1 Fusion Spitzoid Neoplasms , 2017, The American journal of surgical pathology.

[17]  Jennifer D. Hintzsche,et al.  Kinase gene fusions in defined subsets of melanoma , 2017, Pigment cell & melanoma research.

[18]  I. Yeh,et al.  NTRK3 kinase fusions in Spitz tumours , 2016, The Journal of pathology.

[19]  T. Graeber,et al.  CRAF R391W is a melanoma driver oncogene , 2016, Scientific Reports.

[20]  D. Burr,et al.  No rapid audiovisual recalibration in adults on the autism spectrum , 2016, Scientific Reports.

[21]  K. Busam,et al.  Spitz Tumors , 2016, International journal of surgical pathology.

[22]  M. Mihm,et al.  Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy. , 2016, Pathology.

[23]  Quan Quan,et al.  Novel anti-thrombotic agent for modulation of protein disulfide isomerase family member ERp57 for prophylactic therapy , 2015, Scientific Reports.

[24]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[25]  R. Dummer,et al.  TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms , 2015, Scientific Reports.

[26]  I. Yeh,et al.  Clinical, Histopathologic, and Genomic Features of Spitz Tumors With ALK Fusions , 2015, The American journal of surgical pathology.

[27]  P. Stephens,et al.  Melanoma BRAF Fusions—Response , 2014, Clinical Cancer Research.

[28]  I. Yeh,et al.  Melanoma BRAF Fusions—Letter , 2014, Clinical Cancer Research.

[29]  Nicolas Stransky,et al.  The landscape of kinase fusions in cancer , 2014, Nature Communications.

[30]  L. Cerroni,et al.  Clinical and Pathologic Findings of Spitz Nevi and Atypical Spitz Tumors With ALK Fusions , 2014, The American journal of surgical pathology.

[31]  B. Bastian.  The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. , 2014, Annual review of pathology.

[32]  Iwei Yeh,et al.  Kinase fusions are frequent in Spitz tumours and spitzoid melanomas , 2014, Nature Communications.

[33]  P. Stephens,et al.  BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition , 2013, Clinical Cancer Research.

[34]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[35]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[36]  Francesca Demichelis,et al.  Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma , 2010, Nature Medicine.

[37]  D. Pearson,et al.  Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma , 2009, Oncogene.

[38]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[39]  R. Stephens,et al.  Autoregulation of the Raf-1 serine/threonine kinase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.